Pipeline for Retinopathy of Prematurity Therapeutics H1 2017 by Companies Available at ReportsnReports.com

Friday, May 19, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

PUNE, India, May 19, 2017 /PRNewswire/ --

New market report Retinopathy Of Prematurity - Pipeline Review, H1 2017

provide comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Browse 11 Tables and 10 Figures, 3 Companies, spread across 32 pages available at http://www.reportsnreports.com/reports/992878-retinopathy-of-prematurity-pipeline-review-h1-2017.html.

Retinopathy Of Prematurity market companies are Biomar Microbial Technologies, F. Hoffmann-La Roche Ltd and Recordati SpA

Retinopathy Of Prematurity - Drug Profiles includes IB-09A0133, propranolol, R-200 and ranibizumab

Market Retinopathy Of Prematurity key player's reviews involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 9, 4, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Scope: The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology). The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

Order a copy of Retinopathy Of Prematurity - Pipeline Review, H1 2017 research report at http://www.reportsnreports.com/purchase.aspx?name=992878.

The Retinopathy Of Prematurity market pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects and latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology).

Reasons to buy Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology). Classify potential new clients or partners in the target demographic. Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Related Reports: 

Choroidal Neovascularization - Pipeline Review, H1 2017

Bacterial Conjunctivitis - Pipeline Review, H1 2017

Glaucoma - Pipeline Review, H1 2017

Explore more reports on Pharmaceuticals at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact: Ritesh Tiwari 2nd Floor, Metropole Building Next to Inox Theatre Bund Garden Road, Pune - 411013. Maharashtra, India. +1-888-391-5441 sales@reportsandreports.com

Connect with Us:  LinkedIn: http://www.linkedin.com/company/reportsnreports RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store